Samarth Kulkarni - Mar 10, 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ AJ Silver, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Mar 10, 2024
Transactions value $
-$1,108,263
Form type
4
Date filed
3/12/2024, 05:45 PM
Previous filing
Feb 21, 2024
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +19.3K +9.91% 214K Mar 10, 2024 Direct F1
transaction CRSP Common Shares Sale -$767K -9.8K -4.59% $78.26 204K Mar 11, 2024 Direct F2
transaction CRSP Common Shares Options Exercise +9K +4.42% 213K Mar 11, 2024 Direct F1
transaction CRSP Common Shares Sale -$341K -4.58K -2.15% $74.44 208K Mar 12, 2024 Direct F2
holding CRSP Common Shares 200K Mar 10, 2024 The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -19.3K -25% 57.8K Mar 10, 2024 Common Shares 19.3K Direct F1, F3
transaction CRSP Restricted Stock Units Options Exercise -9K -50% 9K Mar 11, 2024 Common Shares 9K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
F4 This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.